DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous
STADA expands branded product strategy
16.09.2014 / 09:00
---------------------------------------------------------------------
Bad Vilbel/Huddersfield, September 16, 2014 - On the occasion of today's
Capital Markets Day, which takes place at STADA's newest subsidiary,
Thornton & Ross, Chief Financial Officer of STADA Helmut Kraft affirms the
Group's focus on the strengthened expansion of the Branded Products
segment. With additional acquisitions, progressing internationalization and
centralized portfolio management, STADA intends to exceed the one billion
euro mark in sales for branded products in the medium term.
"In the future, we will increasingly leverage synergies for the
international positioning of our branded products. With the introduction of
a centralized portfolio management structure and the advantages of
decentralized marketing, we take account of the growing importance of this
segment within the Group. We consistently follow our strategy of launching
existing branded products in new markets and further expanding the
portfolio at the same time", says Helmut Kraft in his presentation.
In line with the topic of focus, STADA's Executive Board invited analysts
to this year's Capital Markets Day held in Huddersfield, the headquarters
of OTC supplier Thornton & Ross. The number 4 in the British OTC market has
been part of the STADA Group since last autumn. Thornton & Ross acts as a
"Center of OTC Excellence" where new branded products are worked on for
Group companies worldwide. "For STADA, Thornton & Ross is not just an ideal
addition in the British market, the company makes a large overall
contribution to the expansion of STADA's branded products strategy with its
long-standing experience and high level of expertise in the area of branded
products", explains Luc Slegers, Senior Vice President Europe at STADA.
In light of current events, Dmitry Efimov, CEO STADA CIS, has informed the
participants of market developments and trends in Russia and has
highlighted the expectations of STADA's Executive Board regarding an
upswing in the local business in the fourth quarter of the current
financial year.
Overall, the Executive Board of STADA affirms its outlook for financial
year 2014 with slight growth in Group sales, adjusted EBITDA and adjusted
net income.
All of the presentations shown at the Capital Markets Day are available on
STADA's website under Investor Relations at: www.stada.com/cmd2014.
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / StadastraÃe 2-18 / 61118 Bad
Vilbel - Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-506
/ e-mail: press@stada.de
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / StadastraÃe 2-18 / 61118 Bad
Vilbel - Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506
/ e-mail: communications@stada.de
Or visit us in the Internet at www.stada.com.
---------------------------------------------------------------------
16.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
287159 16.09.2014
DGAP-News: STADA expands branded product strategy
| Source: EQS Group AG